We are delighted to share the interview to our CEO Agnès Arbat on #Lideratges, Ariadna’s Belver Comin program, where … [Read more...] about Oxolife in the radio
After a year since the start of our clinical trial and after the last milestone of end of recruitment, we want to share … [Read more...] about At OXOLIFE we are celebrating!!
These days the OXOLIFE team is in Milan (Italy) at European Society of Human Reproduction and Embryology (ESHRE) … [Read more...] about Oxolife attend to ESHRE Congress 2022
After 9 months of recruiting women who are looking for pregnancy, we have finally passed our milestone with 403 patients … [Read more...] about At @OXOLIFE we are celebrating!
Our CEO Agnes Arbat is interviewed at IB radio to talk about our OXOART2 Clinical trial. She explains the potential of … [Read more...] about Oxolife in the News
The biotechnology company Oxolife S.L. (Spain), the Energy Balance, Puberty and Reproductive Health research group of … [Read more...] about Oxolife initiates a collaboration with the University of Cordoba and Rutgers, The State University of New Jersey, to develop a treatment to improve women’s fertility
We are delighted to announce that OXOART2, the OXO-001 phase II clinical trial, has already started! As mentioned by … [Read more...] about ANOTHER BIG MILESTONE FOR OXOLIFE
On the 9th of September, we had the pleasure to meet the Czech and Polish investigators in the OXOART2 Investigators … [Read more...] about Good feelings in the investigators meetings
Last Thursday 2nd of September, we had the pleasure to celebrate the first investigator meeting of the phase II clinical … [Read more...] about OXOART2 is here: First Investigators Meeting
OXOLIFE is developing the first drug that will treat female infertility by improving the endometrium to enhance the … [Read more...] about UNPRECEDENTED APPROACH: Oxolife shows up in El Punt Avui